Market Cap 59.76M
Revenue (ttm) 0.00
Net Income (ttm) -12.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 18,900
Avg Vol 11,462
Day's Range N/A - N/A
Shares Out 5.10M
Stochastic %K 54%
Beta 0.49
Analysts Strong Sell
Price Target $39.00

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilima...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 994 8250
Address:
149 Fifth Avenue, Suite 500, New York, United States
OrientBeach
OrientBeach Sep. 19 at 2:45 PM
$INKT From Q2 10-K “We are collaborating with Orphan Drug Consulting to support physician-initiated requests for agenT-797 for individually identified patients. The program expands access for patients with serious unmet medical need and provides MiNK with program revenue for product supplied. Each request is initiated by the treating physician and remains subject to case-by-case Brazilian regulatory authorization . . . product will be supplied on a paid, per-patient basis in accordance with applicable Brazilian access regulations. The program may result in non-promotional income to MiNK while establishing the operational infrastructure needed to support responsible access to agenT-797 in additional international markets”
0 · Reply
svertical1
svertical1 Sep. 19 at 4:16 AM
$INKT >$8B Tam Know what you own. Wall Street doesn’t know…. Grok knows!
0 · Reply
OrientBeach
OrientBeach Sep. 18 at 4:12 PM
$INKT Shares O/S - 5,103,002 Adj Insiders - 2,749,855 Institutions - 275,709 Private Buy - 464,000 in May ’24 Shares available in Public Float - 1,613,438
1 · Reply
OrientBeach
OrientBeach Sep. 18 at 3:57 PM
$INKT Fintel is wrong The company filed a 13-D on Feb ‘24 listing Garo Armen owning 351,432 in the aggregate post split https://investor.minktherapeutics.com/static-files/6b0290d4-4e6a-46e8-b8d4-d6ce301c7265 He has not Awarded himself any shares since this last reporting and represents 6.89% of O/S
0 · Reply
2_logs_higher
2_logs_higher Sep. 18 at 12:14 AM
$AGEN & $INKT fwiw the last mile next thursday, until there needs to be a pivot.
0 · Reply
86Stonk86
86Stonk86 Sep. 17 at 7:17 PM
$INKT die their website update the Pipeline? i dont recall seeing the CDA’s before?
0 · Reply
Dancady1
Dancady1 Sep. 17 at 7:10 PM
$INKT welp ibrx and agen both seeing some gains while inkt consolidates… will inkt ever catch up
0 · Reply
svertical1
svertical1 Sep. 17 at 3:18 PM
$IBRX $INKT Don’t forget, INKT too!
0 · Reply
Dancady1
Dancady1 Sep. 16 at 10:02 PM
$INKT says 430% increase in insider selling … thoughts??
1 · Reply
enkemm
enkemm Sep. 16 at 6:09 AM
$INKT The Edesa phase 3 trial showed the 60-day risk of death was 46% on paridiprubart (Edesa's product) and 59% on placebo. Edesa claimed this as a primary endpoint win. So even with Edesa'a product, life or death is still basically a coin toss. IMO this is NOT GOOD ENOUGH...you have to take it from 60% risk of death to 20% risk of death for it to be a billion dollar baby. That is...go from 3 out of 5 dead to 1 out of 5 dead with the drug. Perhaps I am wrong, but I do not think Edesa is dancing on the ceiling.
1 · Reply
Latest News on INKT
MiNK Therapeutics Earnings Call Transcript: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 5 weeks ago

MiNK Therapeutics Earnings Call Transcript: Q2 2026


MiNK Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 5 weeks ago

MiNK Therapeutics Earnings release: Q2 2026


MiNK Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 5 weeks ago

MiNK Therapeutics Quarterly report: Q2 2026


MiNK Therapeutics Transcript: AGM 2026

Jun 17, 2026, 9:30 AM EDT - 3 months ago

MiNK Therapeutics Transcript: AGM 2026


MiNK Therapeutics doses first patient in agenT-797 trial

2026-05-28T14:12:03.000Z - 3 months ago

MiNK Therapeutics doses first patient in agenT-797 trial


MiNK Therapeutics reports new data on agenT-797 at ATS 2026

2026-05-20T15:15:48.000Z - 4 months ago

MiNK Therapeutics reports new data on agenT-797 at ATS 2026


MiNK Therapeutics Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 4 months ago

MiNK Therapeutics Earnings Call Transcript: Q1 2026


MiNK Therapeutics Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 4 months ago

MiNK Therapeutics Earnings release: Q1 2026


MiNK Therapeutics Quarterly report: Q1 2026

May 15, 2026, 8:30 AM EDT - 4 months ago

MiNK Therapeutics Quarterly report: Q1 2026


MiNK Therapeutics initiates agenT-797 clinical trial

2026-05-14T17:31:11.000Z - 4 months ago

MiNK Therapeutics initiates agenT-797 clinical trial


MiNK Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

MiNK Therapeutics Proxy statement: Proxy filing


MiNK Therapeutics management to meet virtually with B. Riley

2026-04-20T17:05:20.000Z - 5 months ago

MiNK Therapeutics management to meet virtually with B. Riley


MiNK Therapeutics Earnings Call Transcript: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 5 months ago

MiNK Therapeutics Earnings Call Transcript: Q4 2025


MiNK Therapeutics Annual report: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 5 months ago

MiNK Therapeutics Annual report: Q4 2025


MiNK Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 5 months ago

MiNK Therapeutics Earnings release: Q4 2025


3 Penny Stocks to Watch Now, 3/11/26

2026-03-11T14:11:00.000Z - 6 months ago

3 Penny Stocks to Watch Now, 3/11/26

ATPC LGVN


Why Is MiNK Therapeutics Stock (INKT) Up Today?

2026-03-10T12:33:59.000Z - 6 months ago

Why Is MiNK Therapeutics Stock (INKT) Up Today?


MiNK Therapeutics Registration statement: Registration Filing

Dec 10, 2025, 7:00 AM EST - 9 months ago

MiNK Therapeutics Registration statement: Registration Filing


MiNK Therapeutics Earnings Call Transcript: Q3 2025

Nov 14, 2025, 8:30 AM EST - 10 months ago

MiNK Therapeutics Earnings Call Transcript: Q3 2025


MiNK Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 10 months ago

MiNK Therapeutics Quarterly report: Q3 2025


MiNK Therapeutics Earnings release: Q3 2025

Nov 14, 2025, 8:30 AM EST - 10 months ago

MiNK Therapeutics Earnings release: Q3 2025


MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year

2025-11-14T12:35:56.000Z - 10 months ago

MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year


MiNK Therapeutics files $150M mixed securities shelf

2025-11-07T22:00:18.000Z - 10 months ago

MiNK Therapeutics files $150M mixed securities shelf


MiNK Therapeutics reports updated clinical results on agenT-797

2025-11-07T14:05:54.000Z - 10 months ago

MiNK Therapeutics reports updated clinical results on agenT-797


MiNK Therapeutics Registration statement: Registration Filing

Nov 7, 2025, 7:00 AM EST - 10 months ago

MiNK Therapeutics Registration statement: Registration Filing


MiNK Therapeutics appoints John Holcomb to board of directors

2025-09-29T11:45:50.000Z - 11 months ago

MiNK Therapeutics appoints John Holcomb to board of directors


MiNK Therapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q2 2025


MiNK Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Quarterly report: Q2 2025


MiNK Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q2 2025


MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year

2025-08-14T11:40:29.000Z - 1 year ago

MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year


MiNK Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q1 2025


MiNK Therapeutics Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Quarterly report: Q1 2025


MiNK Therapeutics Earnings release: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q1 2025


MiNK Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q4 2024


MiNK Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Annual report: Q4 2024


MiNK Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q4 2024


MiNK Therapeutics Proxy statement: Proxy Filing

Dec 20, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Proxy statement: Proxy Filing

Dec 6, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q3 2024


MiNK Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Quarterly report: Q3 2024


MiNK Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings release: Q3 2024


MiNK Therapeutics Earnings Call Transcript: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q2 2024


MiNK Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Quarterly report: Q2 2024


MiNK Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q2 2024


MiNK Therapeutics Registration statement: Registration Filing

Aug 13, 2024, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Registration statement: Registration Filing


MiNK Reports Second Quarter 2024 Results and Business Update

Aug 13, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Second Quarter 2024 Results and Business Update


MiNK Therapeutics Earnings Call Transcript: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q1 2024


MiNK Therapeutics Quarterly report: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Quarterly report: Q1 2024


MiNK Therapeutics Earnings release: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q1 2024


MiNK Reports First Quarter 2024 Results

May 14, 2024, 7:30 AM EDT - 2 years ago

MiNK Reports First Quarter 2024 Results


MiNK Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Earnings Call Transcript: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q4 2023


MiNK Therapeutics Annual report: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Annual report: Q4 2023


MiNK Therapeutics Earnings release: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q4 2023


MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results


OrientBeach
OrientBeach Sep. 19 at 2:45 PM
$INKT From Q2 10-K “We are collaborating with Orphan Drug Consulting to support physician-initiated requests for agenT-797 for individually identified patients. The program expands access for patients with serious unmet medical need and provides MiNK with program revenue for product supplied. Each request is initiated by the treating physician and remains subject to case-by-case Brazilian regulatory authorization . . . product will be supplied on a paid, per-patient basis in accordance with applicable Brazilian access regulations. The program may result in non-promotional income to MiNK while establishing the operational infrastructure needed to support responsible access to agenT-797 in additional international markets”
0 · Reply
svertical1
svertical1 Sep. 19 at 4:16 AM
$INKT >$8B Tam Know what you own. Wall Street doesn’t know…. Grok knows!
0 · Reply
OrientBeach
OrientBeach Sep. 18 at 4:12 PM
$INKT Shares O/S - 5,103,002 Adj Insiders - 2,749,855 Institutions - 275,709 Private Buy - 464,000 in May ’24 Shares available in Public Float - 1,613,438
1 · Reply
OrientBeach
OrientBeach Sep. 18 at 3:57 PM
$INKT Fintel is wrong The company filed a 13-D on Feb ‘24 listing Garo Armen owning 351,432 in the aggregate post split https://investor.minktherapeutics.com/static-files/6b0290d4-4e6a-46e8-b8d4-d6ce301c7265 He has not Awarded himself any shares since this last reporting and represents 6.89% of O/S
0 · Reply
2_logs_higher
2_logs_higher Sep. 18 at 12:14 AM
$AGEN & $INKT fwiw the last mile next thursday, until there needs to be a pivot.
0 · Reply
86Stonk86
86Stonk86 Sep. 17 at 7:17 PM
$INKT die their website update the Pipeline? i dont recall seeing the CDA’s before?
0 · Reply
Dancady1
Dancady1 Sep. 17 at 7:10 PM
$INKT welp ibrx and agen both seeing some gains while inkt consolidates… will inkt ever catch up
0 · Reply
svertical1
svertical1 Sep. 17 at 3:18 PM
$IBRX $INKT Don’t forget, INKT too!
0 · Reply
Dancady1
Dancady1 Sep. 16 at 10:02 PM
$INKT says 430% increase in insider selling … thoughts??
1 · Reply
enkemm
enkemm Sep. 16 at 6:09 AM
$INKT The Edesa phase 3 trial showed the 60-day risk of death was 46% on paridiprubart (Edesa's product) and 59% on placebo. Edesa claimed this as a primary endpoint win. So even with Edesa'a product, life or death is still basically a coin toss. IMO this is NOT GOOD ENOUGH...you have to take it from 60% risk of death to 20% risk of death for it to be a billion dollar baby. That is...go from 3 out of 5 dead to 1 out of 5 dead with the drug. Perhaps I am wrong, but I do not think Edesa is dancing on the ceiling.
1 · Reply
OrientBeach
OrientBeach Sep. 15 at 2:26 PM
$INKT One of the leading ARDS companies, Edesa, saw its mortality Phase3 date significantly narrow when compared to Phase2 https://www.fiercebiotech.com/biotech/edesa-posts-survival-data-phase-3-respiratory-failure-trial In addition, Rigel which once received $750.0K by the military to further study Fostamatinib for ARDS in Fall of ‘23 has still yet to enrol its military sponsored Phase2 trial https://ctv.veeva.com/study/fostamatinib-for-treating-acute-respiratory-distress-syndrome-ards-in-hospitalized-adults
1 · Reply
OrientBeach
OrientBeach Sep. 15 at 2:10 PM
$INKT Looks like shorts drew down 27.0K shares the last few days in an attempt to shake out Retail https://fintel.io/ss/us/inkt I am speculating that Agent-797 receives a FDA Fast Track designation soon
0 · Reply
OrientBeach
OrientBeach Sep. 14 at 7:27 PM
$INKT With another high volume trading day today … shorts are exiting in droves News must be on the horizon
0 · Reply
OrientBeach
OrientBeach Sep. 14 at 7:01 PM
$INKT Well, well, well, look what I found! A private company made a substanial investment in INKT acquiring 464.0K shares post split in May ’24 https://investor.minktherapeutics.com/static-files/3a649952-959b-4d1a-9cc3-cbfa36d76914 No wonder the daily trading volume is so low. The float has been absorbed
1 · Reply
enkemm
enkemm Sep. 14 at 5:08 PM
$INKT Here is the insiders breakdown: Major Individual Insider Holdings: Garo H. Armen (Founder & Chairman of the Board): Holds the largest position among individual insiders, controlling a significant direct and indirect portion of the remaining insider pool (~4.3% to 6.6% of the company's total outstanding common stock historically). Jennifer S. Buell (President & CEO): 57,942 shares Brian Corvese (Independent Director): 53,137 shares John Baldoni (Insider/Director): 41,193 shares Barbara Ryan (Independent Director): 21,969 shares Other Board Members & Executives (including Peter Behner, Ulf Wiinberg, and John Holcomb): Hold smaller fractional amounts that balance out the rest of the 857,394 share total.
1 · Reply
enkemm
enkemm Sep. 14 at 2:26 PM
$INKT I believe it is a bit more than 51% ownership. Mink insiders own about 16.8% of Mink's 5.1M shares (857,394 shares). Agenus holds about 42.7% (2,177,286 shares). So...about 59.5% of Mink's 5.1M shares are owned by what I consider insiders. Now...perhaps I am wrong, but AI gave me this info.
1 · Reply
OrientBeach
OrientBeach Sep. 14 at 2:00 PM
$INKT Shorts have covered ~35.0K shares in the last six weeks. Considering insiders own 51.0% it could be they are doing so because they are seeing the data https://fintel.io/ss/us/inkt
0 · Reply
svertical1
svertical1 Sep. 11 at 3:30 PM
$INKT Article below is pertinent to NK Cells as well. Both IBRX & INKT are positioned well for the Paradigm change to Immunotherapy! Long overdue. Imagine, any of us could be critically ill with Cancer, Pneumonia/Sepsis with known treatments that work. FDA…your turn.
0 · Reply
Dancady1
Dancady1 Sep. 10 at 8:29 PM
$INKT chart looks good. Some news and volume would be nice
1 · Reply
weichsel1
weichsel1 Sep. 10 at 2:17 PM
$INKT Any news explaining the jump up today?
0 · Reply
kellyc09
kellyc09 Sep. 9 at 5:49 PM
$INKT I remember this stock being $70 not long ago. Took a flyer a few months back so will see if it ever moves hard again.
0 · Reply
svertical1
svertical1 Sep. 9 at 4:01 PM
$INKT Big question, do they have an ARDS drug, or not. Unmet needs see quicker approvals.
0 · Reply